CoChat
Sign Up
Cited by 32

The DOI matches its Crossref record.

GSK3β inhibition and canonical Wnt signaling in mice hearts after myocardial ischemic damage

Badimon, Lina, Casaní, Laura, Camino-Lopez, Sandra, Juan-Babot, Oriol, Borrell-Pages, Maria·2019·PLOS ONE
DOI 10.1371/journal.pone.0218098PMC PMC6586285
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0218098

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 49

  1. L Badimon, 2014, Thrombosis formation on atherosclerotic lesions and plaque rupture, J Intern Med, 276, 618, 10.1111/joim.12296 · DOI
  2. NG Frangogiannis, 2008, The immune system and cardiac repair, Pharmacol Res, 58, 88, 10.1016/j.phrs.2008.06.007 · DOI
  3. S Gessert, 2010, The multiple phases and faces of wnt signaling during cardiac differentiation and development, Circ Res, 107, 186, 10.1161/CIRCRESAHA.110.221531 · DOI
  4. M Borrell-Pagès, 2011, Wnt pathway activation, cell migration and lipid uptake is regulated by LRP5 in human macrophages, Eur Heart J, 32, 2841, 10.1093/eurheartj/ehr062 · DOI · Paper page
  5. X He, 2004, LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way, Development, 131, 1663, 10.1242/dev.01117 · DOI · Paper page
  6. LR Howe, 1999, Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells, Cancer Res, 59, 1572
  7. B Mann, 1999, Target genes of beta-catenin-TCF/LEF signaling in human colorectal carcinomas, Proc Natl Acad Sci U S A, 96, 1603, 10.1073/pnas.96.4.1603 · DOI · Paper page
  8. T Müller, 2002, Regulation of epithelial cell migration and tumor formation by beta-catenin signaling, Exp Cell Res, 280, 119, 10.1006/excr.2002.5630 · DOI
  9. X Zhang, 2001, Regulation of VEGF by the Wnt and K-ras pathways in colonic neoplasia, Cancer Res, 61, 6050
  10. Y Zhai, 2002, Role of beta-catenin/TCF-regulated genes in ovarian endometrioid adenocarcinomas, Am J Pathol, 160, 1229, 10.1016/S0002-9440(10)62550-3 · DOI
  11. F Dell'Accio, 2006, Activation of WNT and BMP signaling in adult human articular cartilage following mechanical injury, Arthritis Res Ther, 8, R139, 10.1186/ar2029 · DOI
  12. M Borrell-Pages, 2014, Cholesterol modulates LRP5 expression in the vessel wall, Atherosclerosis, 235, 363, 10.1016/j.atherosclerosis.2014.05.922 · DOI · Paper page
  13. M Borrell-Pages, 2015, LRP5 and plasma cholesterol levels modulate the canonical Wnt signalling in peripheral blood leukocytes, Immunol Cell Biol, 93, 653, 10.1038/icb.2015.41 · DOI · Paper page
  14. M Borrell-Pages, 2015, LRP5 deficiency downregulates Wnt pathway and promotes aortic lipid accumulation in hypercholesterolemic mice, J Cell Mol Med, 19, 770, 10.1111/jcmm.12396 · DOI · Paper page
  15. M Borrell-Pages, 2016, LRP5/canonical Wnt signalling and healing of ischemic myocardium, Basic Res Cardiol, 111, 167, 10.1007/s00395-016-0585-y · DOI · Paper page
  16. L Barandon, 2003, Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA, Circulation, 108, 2282, 10.1161/01.CIR.0000093186.22847.4C · DOI
  17. L Barandon, 2005, Involvement of FrzA/sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning, Circ Res, 96, 1299, 10.1161/01.RES.0000171895.06914.2c · DOI
  18. L Chen, 2004, Expression of Dishevelled-1 in wound healing after acute myocardial infarction: possible involvement in myofibroblast proliferation and migration, J Cell Mol Med, 8, 257, 10.1111/j.1582-4934.2004.tb00281.x · DOI
  19. K Kobayashi, 2009, Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction, Nat Cell Biol, 11, 46, 10.1038/ncb1811 · DOI
  20. M Mirotsou, 2007, Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair, Proc Natl Acad Sci USA, 104, 1643, 10.1073/pnas.0610024104 · DOI
  21. MP Alfaro, 2008, The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair, Proc Natl Acad Sci USA, 105, 18366, 10.1073/pnas.0803437105 · DOI
  22. JY Hahn, 2006, Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts, J Biol Chem, 281, 30979, 10.1074/jbc.M603916200 · DOI
  23. S Frame, 2001, GSK3 takes centre stage more than 20 years after its discovery, Biochem. J, 359, 1, 10.1042/bj3590001 · DOI · Paper page
  24. CA Grimes, 2001, The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling, Prog. Neurobiol, 65, 391, 10.1016/S0301-0082(01)00011-9 · DOI
  25. BW Doble, 2003, GSK-3: tricks of the trade for a multi-tasking kinase, J. Cell Sci., 116, 1175, 10.1242/jcs.00384 · DOI · Paper page
  26. E Iwahana, 2004, Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei, Eur. J. Neurosci, 19, 2281, 10.1111/j.0953-816X.2004.03322.x · DOI · Paper page
  27. GN Bijur, 2003, Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria, Neuroreport, 14, 2415, 10.1097/00001756-200312190-00025 · DOI
  28. ES Emamian, 2004, Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia, Nat. Genet, 36, 131, 10.1038/ng1296 · DOI
  29. CL Sayas, 1999, The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation, J Biol Chem, 274, 37046, 10.1074/jbc.274.52.37046 · DOI
  30. CL Sayas, 2002, Glycogen synthase kinase-3 is activated in neuronal cells by Gα12 and Gα13 by Rho-independent and Rho-dependent mechanisms, J Neuro, 22, 6863, 10.1523/JNEUROSCI.22-16-06863.2002 · DOI
  31. AV Ougolkov, 2006, Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation, Clin Cancer Res, 12, 5074, 10.1158/1078-0432.CCR-06-0196 · DOI
  32. Q Zhu, 2011, Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo, Prostate, 71, 835, 10.1002/pros.21300 · DOI
  33. SL Holmen, 2004, Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6, Bone Miner Res, 19, 2033, 10.1359/jbmr.040907 · DOI
  34. C Lindvall, 2006, The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis, J Biol Chem, 281, 35081, 10.1074/jbc.M607571200 · DOI
  35. Y Cui, 2011, Lrp5 functions in bone to regulate bone mass, Nat Med, 17, 684, 10.1038/nm.2388 · DOI
  36. X Jiang, 2014, A GSK-3β inhibitor protects against radiation necrosis in mouse brain, Int J Radiat Oncol Biol Phys, 89, 714, 10.1016/j.ijrobp.2014.04.018 · DOI
  37. M Borrell-Pages, 2014, LRP5 negatively regulates differentiation of monocytes through abrogation of Wnt signalling, J Cell Mol Med, 18, 314, 10.1111/jcmm.12190 · DOI
  38. O Varea, 2009, Estradiol Activates β-Catenin Dependent Transcription in Neurons, PLoS ONE, 4, e5153, 10.1371/journal.pone.0005153 · DOI
  39. O Birot, 2003, Exercise-Induced Expression of Vascular Endothelial Growth Factor mRNA in Rat Skeletal Muscle is Dependent on Fibre Type, J Physiol, 552, 213, 10.1113/jphysiol.2003.043026 · DOI
  40. TN Lin, 1997, Prolongation and Enhancement of Postischemic c-fos Expression After Fasting, Stroke, 28, 412, 10.1161/01.STR.28.2.412 · DOI
  41. AH Zea, 2016, Activation of the IL-2 Receptor in Podocytes: A Potential Mechanism for Podocyte Injury in Idiopathic Nephrotic Syndrome?, PLoS ONE, 11, e0157907, 10.1371/journal.pone.0157907 · DOI
  42. H Tong, 2002, Phosphorylation of glycogen synthase kinase-3 beta during preconditionoing through a phosphatidylinositol-3-kinase dependent pathway is cardioprotective, Circ Res, 90, 377, 10.1161/01.RES.0000012567.95445.55 · DOI
  43. ER Gross, 2004, Opioid-induced cardioprotection occurs via glycogen synthase kinase beta during reperfusion in intact rat hearts, Circ Res, 94, 960, 10.1161/01.RES.0000122392.33172.09 · DOI
  44. PS Pagel, 2006, Inhibition of glycogen synthase kinases enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo, Anesth Analg, 102, 1348, 10.1213/01.ane.0000202379.61338.37 · DOI
  45. L Gomez, 2008, Inhibition of GSK3-beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion, Circulation, 117, 2761, 10.1161/CIRCULATIONAHA.107.755066 · DOI
  46. M Juhaszova, 2004, Glycogen synthase kinase 3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore, J Clin Invest, 113, 1534, 10.1172/JCI19906 · DOI
  47. Y Nishino, 2008, Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse, Circ Res, 103, 307, 10.1161/CIRCRESAHA.107.169953 · DOI
  48. CL Antos, 2002, Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo, Proc. Natl. Acad. Sci. USA, 99, 907, 10.1073/pnas.231619298 · DOI
  49. S Kaga, 2006, Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium, J. Mol. Cell. Cardiol., 40, 138, 10.1016/j.yjmcc.2005.09.009 · DOI

Cited by

Sorted by citations

Metadata

Authors
Badimon, L., Casaní, L., Camino-Lopez, S., Juan-Babot, O., & Borrell-Pages, M.
ORCID
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2019-06-20
Volume
14
Issue
6
Pages
e0218098
ISSN
1932-6203
DOI
10.1371/journal.pone.0218098
PMC
PMC6586285
Cited by
32
References
0
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Ministerio de Ciencia e Innovación (SAF2016-76819-R)
  • Instituto de Salud Carlos III (CIBERCV CN16/11/00411, TERCEL RD16/0011/018, FIS2016-02014)
  • Generalitat de Catalunya (2014SGR1303)
  • Sociedad Española de Cardiología (SEC2015)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review